Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
Suzhou taps into international travel marketWanderlust unleashed after restrictions easedLawsuit by Chicago Tribune staffers claims race and sex discriminationChina boasts 2 mln beds in integrated medical, elderly care institutionsNew Delhi heat wave: City records up to 47.1 degrees CelsiusJudge and Stanton homer to back effective Cortes as streaking Yankees top White Sox 4The Sun score 15 straight points in the fourth quarter to pull away from the Mystics 84Blind fish species found in China's underground streamGlobal tourism industry to get boost from Chinese travelers, says WTTC CEOJudge pushes decision to next week on Alec Baldwin's indictment in fatal 2021 shooting